linjc16/ctgov huggingface dataset:
Arterial dP/dt Dependency on Loading Conditions

Study Overview
=================
Brief Summary
-----------------
In the present study we aim to investigate the changes of the arterial dP/dtmax induced by fluids and vasoactive drugs during abdominal surgery

Official Title
-----------------
RESPONSE OF ARTERIAL dP/dt TO FLUIDS AND VASOACTIVE DRUGS DURING ABDOMINAL SURGERY: A PROSPECTIVE PILOT STUDY

Conditions
-----------------
Intraoperative Hemodyamic Monitoring

Intervention / Treatment
-----------------
* Device: arterial dp/dtmax


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients scheduled for abdominal surgery informed consent acceptance - Exclusion Criteria: BMI> 30 Kg /m2; Atrial Fibrillation; Congestive heart failure with FE <35% and/or NYHA≥3; Severe known cardiac valve disease; Emergency surgery Shock or any acute conditions who required admission intensive care unit

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: arterial dp/dtmax|to assess the variations of the arterial dp/dt max after drugs or fluids administration|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| dp/dt fluids dependency | measurement of dp/dtmax after fluid challenge | intraoperative | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
emodinamica
Lower Urinary Tract Symptoms in Males Living With HIV

Study Overview
=================
Brief Summary
-----------------
The primary aim of this study is to learn whether the frequency of lower urinary tract symptoms differ between the males with seronegativity for HIV and males living with HIV.

Official Title
-----------------
Males Living With HIV and LUTS: A Case-control Study.

Conditions
-----------------
HIV Seropositivity, Lower Urinary Tract Symptoms

Intervention / Treatment
-----------------
* Diagnostic Test: Questionnaires


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients above 18 years old Exclusion Criteria: Non-Turkish speakers Previous surgeries or medications for lower urinary tract symptoms

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Males living with HIV<br>Males living with HIV and followed by infectious diseases clinic will be directed to Urology department. | Diagnostic Test: Questionnaires<br>* MLWH and control groups were asked to complete the following questionnaires: International Consultation on Incontinence Questionnaire - Male Lower Urinary Tract Symptoms (ICIQ-MLUTS), ICIQ-Short Form (ICIQ-SF), International Prostate Symptom Score (IPSS), King's Healthcare Questionnaire (KHQ), 8-item Overactive Bladder Questionnaire (OAB-V8), Urogenital Distress Inventory 6 and 7 (UDI 6 and UDI 7).<br>|
| HIV-negative controls<br>Males admitted to Infectious Diseases clinic and documented to be HIV-negative. | Diagnostic Test: Questionnaires<br>* MLWH and control groups were asked to complete the following questionnaires: International Consultation on Incontinence Questionnaire - Male Lower Urinary Tract Symptoms (ICIQ-MLUTS), ICIQ-Short Form (ICIQ-SF), International Prostate Symptom Score (IPSS), King's Healthcare Questionnaire (KHQ), 8-item Overactive Bladder Questionnaire (OAB-V8), Urogenital Distress Inventory 6 and 7 (UDI 6 and UDI 7).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Questionnaires | International Consultation on Incontinence Questionnaire | Once | 
| Questionnaires | Male Lower Urinary Tract Symptoms (ICIQ-MLUTS) | Once | 
| Questionnaires | ICIQ-Short Form (ICIQ-SF) | Once | 
| Questionnaires | International Prostate Symptom Score (IPSS) | Once | 
| Questionnaires | King's Healthcare Questionnaire (KHQ) | Once | 
| Questionnaires | 8-item Overactive Bladder Questionnaire (OAB-V8) | Once | 
| Questionnaires | Urogenital Distress Inventory 6 and 7 (UDI 6 and UDI 7). | Once |
CORONABED.BOT -COVID-19: an Automation Project Using Artificial Intelligence for Early Diagnosis of Clinical Evolution From SARS-CoV-2

Study Overview
=================
Brief Summary
-----------------
The aim of the CORONA.BOT project is to exploit the Artificial Intelligence methods of Generator Real World Data Facility to automatically extract structured and unstructured data from hospital databases and to implement an early risk assessment (warning system) regarding the negative outcome for patients infected with SARS-CoV-2. The objective of CORONABED.BOT is to analyze the care pathways of patients from the same cohort as CORONA.BOT, in order to identify the total length of stay, intensive care occupations and flows between departments, based on variables demographics and first entry clinics Early identification of patients with symptoms compatible with SARS-CoV-2 infection will enable more rapid activation of isolation procedures, contact monitoring/contact history and decisions on the most appropriate clinical pathway in terms of type of treatment and unit. Similarly, the identification of factors correlated with worse outcomes will allow more effective planning for the use of critical resources (such as intensive care and others).

Official Title
-----------------
CORONABED.BOT: an Automation Project Using Artificial Intelligence for Early Diagnosis of Clinical Evolution From SARS-CoV-2

Conditions
-----------------
SARS-CoV-1 Infection

Intervention / Treatment
-----------------
* Other: Artificial Intelligence methods


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult patients (18 years of age or older) admitted to the Gemelli and Columbus Polyclinic diagnosis of SARS-CoV-2 infection (suspected cases will also be included). Exclusion Criteria: aaaa

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Artificial Intelligence methods|The aim of the CORONA.BOT project is to exploit the Artificial Intelligence methods of Generator Real World Data Facility to automatically extract structured and unstructured data from hospital databases and to implement an early risk assessment (warning system) regarding the negative outcome for patients infected with SARS-CoV-2.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the implementation of prediction models | tThe DataMart built will allow the creation of predictive models both for diagnosis of SARS-coV-2 pneumonia as well as death | 24 months |
A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide.

Study Overview
=================
Brief Summary
-----------------
The efficacy and safety of chidamide in first-line maintenance therapy for PTCL will be assessed through a retrospective case analysis.

Detailed Description
-----------------
The study design belongs to a retrospective study, collecting information on patients with PTCL who were diagnosed and treated with chidamide as maintenance therapy at our center. The collected data includes age, gender, previous treatment regimens, results of auxiliary examinations (such as blood routine, biochemistry, bone marrow cytology, pathology, flow cytometry, NGS, etc.), as well as PET-CT images. The safety and efficacy of Chidemide as first-line maintenance therapy in PTCL will be analyzed.

Official Title
-----------------
A Retrospective (Non-interventional) Clinical Study on the First-line Maintenance Treatment of Peripheral T-cell Lymphoma (PTCL) With Chidamide.

Conditions
-----------------
PTCL

Intervention / Treatment
-----------------
* Drug: chidamide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: (1) Age: 18 years and older; (2) Gender: Male/Female; (3) Diagnosed with PTCL; (4) Received chidamide as maintenance therapy after first-line treatment. Exclusion Criteria: (1) Patients with other types of lymphomas; (2) Pregnant women.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: chidamide|This subset of patients received chidamide as first-line maintenance therapy.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PFS | progression free survival | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| OS | overall survival | 2 years | 
| CR | complete remission | 2 years | 
| DOR | duration of remission | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
chidamide, maintenance treatment
Prothrombin Complex Concentrate vs Fresh Frozen Plasma in Goal-directed Bleeding Management in Liver Transplantation Surgery

Study Overview
=================
Brief Summary
-----------------
The primary endpoint of this study is the completion time of hemostasis treatment when administered Fresh frozen plasma (FFP) and frozen powder coagulation factor concentrate (PCC) in goal-directed bleeding management for liver transplantation surgery.

Official Title
-----------------
Prothrombin Complex Concentrate and Fresh Frozen Plasma in Viscoelastic Test-based Goal-directed Bleeding Management in Liver Transplantation Surgery

Conditions
-----------------
Liver Diseases

Intervention / Treatment
-----------------
* Biological: fresh frozen plasma
* Biological: prothrombin complex concentrate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Liver disease undergoing Liver transplantation Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: fresh frozen plasma<br>according to the Thromboelastography (TEG) test, CK r-time prolongation, fresh frozen plasma transfusion (FFP) is performed | Biological: fresh frozen plasma<br>* transfusion of fresh frozen plasma<br>|
| Experimental: prothrombin complex concentrate<br>according to the Thromboelastography (TEG) test, CK r-time prolongation, prothrombin complex concentrate (PCC) is administered | Biological: prothrombin complex concentrate<br>* prothrombin complex concentrate administration<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| duration from the time diagnosing r-time prolongation to the time achieving bleeding control |  | 1 min | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Red Blood Cell amount | Red Blood Cell transfusion amount during surgery | 1 hour | 
| FFP amount | FFP transfusion amount during surgery | 1 hour | 
| Platelet amount | Platelet transfusion amount during surgery | 1 hour | 
| r-time | CK r-time after PCC or FFP | 10 min | 
| CRT-MA | CRT-MA after PCC or FFP | 10 min | 
| CFF-MA | CFF-MA after PCC or FFP | 10 min | 
| Bleeding | Postoperative bleeding amount | 6 hour | 
| oxygenation profile | PaO2/FiO2 ratio | 1 hour |
OCT in Open Fracture and Infected Fracture

Study Overview
=================
Brief Summary
-----------------
This is a pilot prospective, observational study of patients with open or infected fracture evaluating the feasibility and acceptability of OCT, a light-based imaging modality that requires no drug or contrast agent.

Official Title
-----------------
Optical Coherence Tomography Imaging to Visualize Bacteria or Biofilm on Hardware, Bone and Soft Tissue in Open Fracture and Infected Fracture

Conditions
-----------------
Trauma Injury, Trauma, Open Fracture, Fracture Infection

Intervention / Treatment
-----------------
* Procedure: Open Fracture
* Procedure: Infected Fracture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 years or older Open fracture Fracture Related Infection Exclusion Criteria: Metatarsal fractures

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Open Fracture<br>High energy open fracture. | Procedure: Open Fracture<br>* Patients 18 years of age or older with open fracture. Provision of informed consent.<br>|
| Infected Fracture<br>Infected open or closed fracture. | Procedure: Infected Fracture<br>* Patients 18 years of age or older with infected fracture. Provision of informed consent.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Feasibility and acceptability of OCT imaging | The primary objective of this work is to demonstrate feasibility, acceptability, and preliminary effectiveness of Optical Coherence Tomography (OCT) to image bacteria and biofilm. Data will be analyzed accordingly: The association between optical imaging parameters (particularly around biofilm and bacterial contamination) and (1) surgical wound severity and (2) development of infection or treatment failure for infection. | 36 months |
Empathy Levels Among Undergraduate Medical Students in Karachi, Pakistan - a Cross-sectional Study

Study Overview
=================
Brief Summary
-----------------
Empathy is a concept native to the field of medicine. However, over the course of medical school, empathy levels are expected to decline. The aim of this study was to assess the empathy levels amongst medical students in relation to their year of study and specialties of choice in the future. A cross-sectional study was conducted to assess empathy levels among students from medical colleges in Karachi, Pakistan, using an online survey. The total duration of the study was two months. The authors analyzed the data using SPSS version 20. A total of 463 undergraduate medical students participated in this survey.

Official Title
-----------------
Empathy Levels Among Undergraduate Medical Students in Karachi, Pakistan - a Cross-sectional Study

Conditions
-----------------
Empathy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: undergraduate medical students Exclusion Criteria: all the remaining population

Ages Eligible for Study
-----------------
Minimum Age: 17 Years
Maximum Age: 24 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Empathy score on the Jefferson Scale of Empathy (JSE) | The total score range of the JSE is 20-140. Each factor of the questionnaire attributes to both positive and negatively phrased questions with '1' signifying 'strongly disagree' and '7' signifying 'strongly agree'. | June 2022 - July 2022 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
empathy, medical students, Pakistan, surveys and questionnaires, observational study
Development of a Scale for Cancer Patients' Willingness to Voluntarily Participate in Drug Clinical Trials

Study Overview
=================
Brief Summary
-----------------
The goal of this observational study is to develop a scale for cancer patients' willingness to voluntarily participate in drug clinical trials and evaluate its reliability and validity.

Official Title
-----------------
Development and Reliability and Validity Evaluation of a Scale for Cancer Patients' Willingness to Voluntarily Participate in Drug Clinical Trials

Conditions
-----------------
Cancer Patients' Willingness to Voluntarily Participate in Drug Clinical Trials

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18-80 years old (including boundary values); Tumor patients with clear diagnosis; Volunteer to participate in this study and sign an informed consent form. Exclusion Criteria: Patients with unclear consciousness; Patients who are unable to correctly understand and answer questions; Vulnerable subjects include: students and subordinates of researchers, military personnel, prisoners, patients with incurable diseases, patients in critical situations, those admitted to welfare institutions, homeless individuals, minors, and those who are unable to provide informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| A semi-structured interview | A semi-structured interview is conducted to investigate the willingness of cancer patients to participate in drug clinical trials and its influencing factors. The researcher will analyze the interview results and summarize several themes that reflect the willingness. | 3 months |
The Study of Bemnifosbuvir in Healthy Japanese Subjects

Study Overview
=================
Brief Summary
-----------------
This study will assess the safety, tolerability and pharmacokinetics (PK) of Bemnifosbuvir in healthy adult Japanese subjects

Official Title
-----------------
A Phase 1, Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Bemnifosbuvir in Healthy Adult Japanese Subjects

Conditions
-----------------
Healthy Volunteer Study

Intervention / Treatment
-----------------
* Drug: Bemnifosbuvir (BEM)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must agree to use two methods of birth control from Screening through 90 days after administration of the last dose of study drug Females must have a negative pregnancy test at Screening and prior to dosing Minimum body weight of 50 kg and body mass index (BMI) of 18-32 kg/m2 Willing to comply with the study requirements and to provide written informed consent The subject must have been born in Japan and have both parents and 4 grandparents of Japanese descent The subject must have lived outside of Japan for no more than 10 years Exclusion Criteria: Pregnant or breastfeeding Infected with hepatitis B virus, hepatitis C virus, HIV or COVID-19 Abuse of alcohol or drugs Use of other investigational drugs within 28 days of dosing Other clinically significant medical conditions or laboratory abnormalities

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 64 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Bemnifosbuvir (BEM)<br>oral tablet | Drug: Bemnifosbuvir (BEM)<br>* BEM administered BID for 4 days and QD on Day 5 (9 consecutive doses)<br>* Other names: AT-527;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pharmacokinetics (PK) of BEM Maximum plasma concentration (Cmax) |  | Day 1, Day 5 | 
| Pharmacokinetics (PK) of BEM Area under the plasma concentration-time curve (AUC) |  | Day 1, Day 5 |